Regulation of Glioma Cells Migration by DYRK2

Overview

Journal Neurochem Res

Specialties Chemistry
Neurology

Date 2017 Jul 6

PMID 28677030

Citations 10

Authors

Yifen Shen

Li Zhang

Donglin Wang

Yifeng Bao

Chao Liu

Zhiwei Xu

Wei Huang

Chun Cheng

Affiliations

Soon will be listed here.

Abstract

Dual-specificity tyrosine-regulated kinase 2 (DYRK2), a protein kinase that phosphorylates its substrates on serine/threonine, is expressed in numerous human tumors, but little is known about its role in the pathophysiology of glioma. In this study, we made an effort to explore the expression and function in human glioma. Western blot and immunohistochemistry analysis were performed to investigate the expression of DYRK2 protein in glioma tissues in 84 patients. Wound healing and transwell assay were carried out to determine the cell migration ability. We showed that the level of DYRK2 was significantly decreased in high-grade glioma tissues compared with low-grade tissues. In addition, the expression level of DYRK2 was positively correlated with glioma pathological grade and E-cadherin expression. Kaplane-Meier analysis revealed that low expression of DYRK2 was related to poor prognosis of glioma patients. Furthermore, wound healing and transwell assay revealed that DYRK2 could suppress cell migration and affect the expression levels of E-cadherin and vimentin through PI3K/AKT/GSK3β signaling pathway. Taken together, our results implied that DYRK2 could serve as a promising prognostic biomarker as well as a potential therapeutical target of glioma.

Citing Articles

The construction of a novel prognostic prediction model for glioma based on GWAS-identified prognostic-related risk loci.

Wei J, Li Y, Zhou W, Ma X, Hao J, Wen T Open Med (Wars). 2024; 19(1):20240895.

PMID: 38584840 PMC: 10996933. DOI: 10.1515/med-2024-0895.

Dual specificity kinase DYRK3 regulates cell migration by influencing the stability of protrusions.

Ramella M, Ribolla L, Surini S, Sala K, Tonoli D, Cioni J iScience. 2024; 27(4):109440.

PMID: 38510137 PMC: 10952033. DOI: 10.1016/j.isci.2024.109440.

Roles of dual specificity tyrosine-phosphorylation-regulated kinase 2 in nervous system development and disease.

Santos-Duran G, Barreiro-Iglesias A Front Neurosci. 2022; 16:994256.

PMID: 36161154 PMC: 9492948. DOI: 10.3389/fnins.2022.994256.

DEAD-Box RNA Helicases DDX3X and DDX5 as Oncogenes or Oncosuppressors: A Network Perspective.

Secchi M, Lodola C, Garbelli A, Bione S, Maga G Cancers (Basel). 2022; 14(15).

PMID: 35954483 PMC: 9367324. DOI: 10.3390/cancers14153820.

Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 with a highly selective inhibitor for the treatment of prostate cancer.

Yuan K, Li Z, Kuang W, Wang X, Ji M, Chen W Nat Commun. 2022; 13(1):2903.

PMID: 35614066 PMC: 9133015. DOI: 10.1038/s41467-022-30581-4.

References

Gwack Y, Sharma S, Nardone J, Tanasa B, Iuga A, Srikanth S . A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT. Nature. 2006; 441(7093):646-50. DOI: 10.1038/nature04631. View

Jovcevska I, Kocevar N, Komel R . Glioma and glioblastoma - how much do we (not) know?. Mol Clin Oncol. 2014; 1(6):935-941. PMC: 3916171. DOI: 10.3892/mco.2013.172. View

Kuhnt D, Becker A, Ganslandt O, Bauer M, Buchfelder M, Nimsky C . Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance. Neuro Oncol. 2011; 13(12):1339-48. PMC: 3223093. DOI: 10.1093/neuonc/nor133. View

Miller C, Aggarwal S, Lin T, Dagenais S, Contreras J, Orringer M . Amplification and overexpression of the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas. Cancer Res. 2003; 63(14):4136-43. View

Wijnhoven B, Dinjens W, Pignatelli M . E-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg. 2000; 87(8):992-1005. DOI: 10.1046/j.1365-2168.2000.01513.x. View

Enomoto Y, Yamashita S, Yoshinaga Y, Fukami Y, Miyahara S, Nabeshima K . Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer. Tumour Biol. 2014; 35(11):11021-5. DOI: 10.1007/s13277-014-2413-z. View

Weiss C, Marco M Ochs , Hagenmueller M, Streit M, Malekar P, Riffel J . DYRK2 negatively regulates cardiomyocyte growth by mediating repressor function of GSK-3β on eIF2Bε. PLoS One. 2013; 8(9):e70848. PMC: 3762802. DOI: 10.1371/journal.pone.0070848. View

Liang Y, Jing Z, Deng H, Li Z, Zhuang Z, Wang S . Soluble epoxide hydrolase inhibition ameliorates proteinuria-induced epithelial-mesenchymal transition by regulating the PI3K-Akt-GSK-3β signaling pathway. Biochem Biophys Res Commun. 2015; 463(1-2):70-5. DOI: 10.1016/j.bbrc.2015.05.020. View

Mimoto R, Taira N, Takahashi H, Yamaguchi T, Okabe M, Uchida K . DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail. Cancer Lett. 2013; 339(2):214-25. DOI: 10.1016/j.canlet.2013.06.005. View

10.

Wang Y, Wu Y, Miao X, Zhu X, Miao X, He Y . Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma. Int J Biol Macromol. 2015; 81:809-17. DOI: 10.1016/j.ijbiomac.2015.08.067. View

11.

Yamashita S, Chujo M, Moroga T, Anami K, Tokuishi K, Miyawaki M . DYRK2 expression may be a predictive marker for chemotherapy in non-small cell lung cancer. Anticancer Res. 2009; 29(7):2753-7. View

12.

VAN Roy F, Berx G . The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci. 2008; 65(23):3756-88. PMC: 11131785. DOI: 10.1007/s00018-008-8281-1. View

13.

Taira N, Nihira K, Yamaguchi T, Miki Y, Yoshida K . DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. Mol Cell. 2007; 25(5):725-38. DOI: 10.1016/j.molcel.2007.02.007. View

14.

Jansen M, Yip S, Louis D . Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol. 2010; 9(7):717-26. PMC: 3079431. DOI: 10.1016/S1474-4422(10)70105-8. View

15.

Yang L, Liu M, Deng C, Gu Z, Gao Y . Expression of transforming growth factor-β1 (TGF-β1) and E-cadherin in glioma. Tumour Biol. 2012; 33(5):1477-84. DOI: 10.1007/s13277-012-0398-z. View

16.

Perez M, Garcia-Limones C, Zapico I, Marina A, Schmitz M, Munoz E . Mutual regulation between SIAH2 and DYRK2 controls hypoxic and genotoxic signaling pathways. J Mol Cell Biol. 2012; 4(5):316-30. DOI: 10.1093/jmcb/mjs047. View

17.

Zhong Z, Hu Z, Jiang Y, Sun R, Chen X, Chu H . Interleukin-11 promotes epithelial-mesenchymal transition in anaplastic thyroid carcinoma cells through PI3K/Akt/GSK3β signaling pathway activation. Oncotarget. 2016; 7(37):59652-59663. PMC: 5312338. DOI: 10.18632/oncotarget.10831. View

18.

Zhou S, Zhou Z, Hu Z, Li X, Huang X, Wang Z . CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling. Cancer Lett. 2014; 358(2):124-135. DOI: 10.1016/j.canlet.2014.11.044. View

19.

Rock K, McArdle O, Forde P, Dunne M, Fitzpatrick D, ONeill B . A clinical review of treatment outcomes in glioblastoma multiforme--the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival?. Br J Radiol. 2012; 85(1017):e729-33. PMC: 3487092. DOI: 10.1259/bjr/83796755. View

20.

Varjosalo M, Bjorklund M, Cheng F, Syvanen H, Kivioja T, Kilpinen S . Application of active and kinase-deficient kinome collection for identification of kinases regulating hedgehog signaling. Cell. 2008; 133(3):537-48. DOI: 10.1016/j.cell.2008.02.047. View